India, June 18 -- With your core strength being injectables and complex formulations, how is Invengene visualising new product launches and investments in FY 2026-27?

As we are transitioning from a strong foundation-building phase into active commercialisation, this is a significant year for the company. Our pipeline comprises 15 injectable products in development across therapy areas including oncology, antifungals, antibiotics, CNS, and hormonal therapy. We expect to advance several of these to the regulatory filing stage across multiple markets this year.

On the R&D front, we continue to invest in our formulation facility in Thane, a 18,000 sq ft centre that houses over 40 scientists. The focus is firmly on formulation complexity- li...